Tech
PharmAust Limited (ASX:PAA) is a clinical-stage biotechnology company developing therapeutics for human and animal health applications.
The company is focused on repurposing monepantel (MPL) for human neurodegenerative diseases and treating cancer in dogs. MPL is a potent and safe inhibitor of the mTOR pathway. This pathway plays a central role in cell growth and proliferation of cancer cells and degenerating neurons. The mTOR pathway regulates the cellular “cleaning process”, where toxic protein is broken down into macromolecules to be reused. This autophagic process is disrupted in most neurodegenerative diseases, including motor neurone disease (MND/ALS).
PAA’s lead MPL program is for the treatment of MND/ALS, a rare, incurable disease. The company is currently completing a Phase 1 study in patients with MND/ALS. PAA anticipates starting a Phase 2 study in H1 2024 that could lead to accelerated approval with the US Food and Drug Administration in 2026. PAA is preparing to start a pivotal field trial in dogs with B-Cell Lymphoma to enable product registration in the US in 2025. PAA has previously successfully completed a Phase 1 oncology clinical study of monepantel in humans and pilot studies in canine cancer.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
PharmAust headed for a ‘Who’s a Good Boy?’ as positive Monepantel canine trials progress
Health & Biotech
PharmAust and FightMND band together to fight against Motor Neurone Disease
Health & Biotech
PharmAust’s subsidiary Epichem appoints new GM as it sets eyes on new commercial opportunities
Health & Biotech
PharmAust accelerates MPL clinical trials in fights against Covid and Motor Neuron Disease
Health & Biotech
PharmAust inks deal with Radium Capital to bag up-front R&D tax claim
Health & Biotech
PharmAust set for Phase 1 Motor Neurone Disease trial as Monepantel tablets arrive
News
Market Highlights and 5 ASX Small Caps to watch on Monday
Health & Biotech
PharmAust expands canine trial of Monepantel to the US, expediting the close out of Phase 2 study
News
Meet the pain: Eddy quaffed all these small cap quarterlies and we saved you the best bits
Health & Biotech
PharmAust confirms cash boost for Phase 1 trials, with ATO approval for federal R&D refund
Health & Biotech
Bring it on: PharmAust to start Phase 1 trial after first instalment lands from FightMND
Health & Biotech
Similarities with our pets could offer giant breakthroughs in cancer research, says PharmAust
Health & Biotech
PharmAust ships first batch of MPL to the US, gets ready for two upcoming clinical trials
News
Market Highlights and 5 ASX Small Caps to watch on Tuesday
Health & Biotech
Preliminary results show PharmAust’s monepantel drug is effective against leukaemia virus HTLV-1
Health & Biotech
PharmAust gets massive expertise boost as final preparations begin for COVID-19 clinical trial
Health & Biotech